Search filters

Filters
Clear All

Phase

  • 10
  • 16
  • 17
  • 11
  • 21
  • 79
  • 37
  • 3
  • 2
  • 74
  • 77
  • 2

Found 79 Chemotherapy trials

A listing of Chemotherapy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

18 years - 99 years
All genders
Interventional
The purpose of this research study is to compare the performance of the investigational (experimental) tricuspid valve repair system plus optimal drug therapy with optimal drug therapy alone. Participants will be randomly assigned to treatment with either the TriClip device (device group) or No TriClip device (control group). Participants will …
 Open Label Study Investigating the Efficacy and Safety of Roxadustat for Treatment of Anemia in Patients Receiving Chemotherapy Treatment for Non-Myeloid Malignancies
18 years - 99 years
All genders
Phase 2
The main purpose of this study is to find out if the experimental drug roxadustat (also known as FG-4592) is safe and effective for potentially treating anemia in people receiving chemotherapy treatments for cancer. 800x600 Normal 0 false false false EN-US X-NONE X-NONE MicrosoftInternetExplorer4 In order to take part in …
99 years or below
All genders
1. To determine the feasibility of integrating a PGx panel test in the EMR with a pharmacist PGx e-consult. 2. Determine the fidelity to genotype-guided pharmacotherapy recommendations. 3. To determine if PGx testing will improve the patient self-reported numeric pain scores 4. To determine if PGx testing will reduce MME …
 Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)  A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
99 years or below
All genders
Phase 3
The purpose of this study is to find if adding the study drug, nivolumab (also known as OPVIDO), will limit lung cancer from growing back in patients with early stage non-small cell lung cancer. Nivolumab is a drug that may turn on the body's immune system to attack any cancer …
 UPCC 06717 / AMC 101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
18 years - 64 years
All genders
Phase 1
Non-Hodgkin lymphoma  is a potentially curable condition with standard cancer treatment drugs (chemotherapy) and steroids. Standard lymphoma treatment includes chemotherapy, or cancer-fighting drugs, called etoposide, vincristine, cyclophosphamide, prednisone and doxorubicin (called EPOCH).  
 A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents With Either Pembrolizumab in Combination With Chemotherapy or With Pembrolizumab Alone in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
18 years - 99 years
All genders
Interventional
This is an umbrella study designed to learn more about how well different drugs work in non-small cell lung cancer. This study will test MK-4830, MK7-684, and MK-5890 with pembrolizumab and standard chemotherapy or with pembrolizumab alone in subjects with advanced NSCLC.
99 years or below
All genders
Phase 3
The primary objective is to compare the PFS of patients randomized to MIRV vs. IC Chemo. Secondary objectives include: To compare the ORR of patients randomized to MIRV vs. IC Chemo, to compare OS of patients randomized to MIRV vs. IC Chemo, and to compare the primary patient-reported outcome (PRO) …
99 years or below
All genders
Phase 2
A multicenter, open label, randomized phase 2 study of I-131-1095 radiotherapy (less than or equal to 100 mCi/dose) every 8 weeks for up to 4 doses in combination with enzalutamide compared to enzalutamide alone in patients with progressive mCRPC. Patients must have documented progression on abiraterone and be indicated for …
 A Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants with Gastrointestinal Malignancies
18 years - 99 years
All genders
Phase 1
Interventional
A study to evaluate the safety, tolerability, PK, pharmacodynamics, and clinical activity of AB680 (CD73 inhibitor) in combination with AB122 (programmed cell death-1 inhibitor) and standard chemotherapy (nab-paclitaxel [NP] and gemcitabine [Gem]) in participants with advanced pancreatic cancer.